TRKA (G667C)
Sign in to save this workspaceNTRK1 · Variant type: point · HGVS: p.G667C
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Nintedanib | 98.5% | 1.5% | 90.23 |
| 2 | Ponatinib | 98.1% | 1.9% | 78.23 |
| 3 | Entrectinib | 97.0% | 3.0% | 93.69 |
| 4 | Cabozantinib | 96.4% | 3.6% | 92.73 |
| 5 | Sunitinib | 95.9% | 4.1% | 91.73 |
| 6 | Repotrectinib | 95.5% | 4.5% | 84.21 |
| 7 | Gilteritinib | 95.3% | 4.7% | 88.97 |
| 8 | Pacritinib | 95.2% | 4.8% | 88.64 |
| 9 | Sorafenib | 93.5% | 6.5% | 96.72 |
| 10 | Defactinib | 90.9% | 9.1% | 92.68 |
| 11 | Alectinib | 90.2% | 9.8% | 95.49 |
| 12 | Bosutinib | 89.9% | 10.1% | 87.22 |
| 13 | Crizotinib | 86.9% | 13.1% | 91.39 |
| 14 | Pralsetinib | 86.0% | 14.0% | 93.43 |
| 15 | Tivozanib | 85.6% | 14.4% | 92.42 |
| 16 | Regorafenib | 85.0% | 15.0% | 95.99 |
| 17 | Quizartinib | 81.3% | 18.7% | 99.50 |
| 18 | Fedratinib | 78.2% | 21.8% | 96.21 |
| 19 | Fostamatinib | 74.9% | 25.1% | 96.74 |
| 20 | Axitinib | 74.2% | 25.8% | 93.23 |
| 21 | Ripretinib | 73.8% | 26.2% | 92.95 |
| 22 | Alpelisib | 70.2% | 29.8% | 97.22 |
| 23 | Darovasertib | 69.0% | 31.0% | 96.99 |
| 24 | Dabrafenib | 65.5% | 34.5% | 94.74 |
| 25 | Tenalisib | 56.1% | 43.9% | 97.98 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Nintedanib | 98.5% | 93.8% | +4.7% |
| Ponatinib | 98.1% | 98.4% | -0.3% |
| Entrectinib | 97.0% | 99.0% | -2.0% |
| Cabozantinib | 96.4% | 93.6% | +2.8% |
| Sunitinib | 95.9% | 82.8% | +13.1% |
| Repotrectinib | 95.5% | 98.9% | -3.4% |
| Gilteritinib | 95.3% | 92.6% | +2.7% |
| Pacritinib | 95.2% | 89.4% | +5.7% |
| Sorafenib | 93.5% | — | — |
| Defactinib | 90.9% | 80.3% | +10.6% |
| Alectinib | 90.2% | — | — |
| Bosutinib | 89.9% | 67.0% | +23.0% |
| Crizotinib | 86.9% | 95.8% | -9.0% |
| Pralsetinib | 86.0% | 98.7% | -12.7% |
| Tivozanib | 85.6% | 85.7% | -0.1% |
| Regorafenib | 85.0% | — | — |
| Quizartinib | 81.3% | — | — |
| Fedratinib | 78.2% | 56.2% | +22.0% |
| Fostamatinib | 74.9% | — | — |
| Axitinib | 74.2% | — | — |
| Ripretinib | 73.8% | 93.6% | -19.8% |
| Alpelisib | 70.2% | 97.5% | -27.3% |
| Darovasertib | 69.0% | — | — |
| Dabrafenib | 65.5% | — | — |
| Tenalisib | 56.1% | 59.0% | -2.9% |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.8ms